Advanced or Metastatic Breast Cancer (DBCOND0041978)

Identifiers

Synonyms

Not Available

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
Capecitabine	A nucleoside metabolic inhibitor indicated to treat different gastrointestinal, including pancreatic cancer, and breast cancer.	Thymidylate synthasetarget Thymidine phosphorylaseenzyme Cytidine deaminaseenzyme Liver carboxylesterase 1enzyme Cytochrome P450 2C9enzyme DNAtarget RNAtarget Albumincarrier Uridine phosphorylase 1enzyme Uridine phosphorylase 2enzyme Thymidylate synthasetarget
Fulvestrant	An estrogen receptor antagonist used to treat HR+ breast cancer that may also be HER2-.	Estrogen receptortarget Cytochrome P450 3A4enzyme UDP-glucuronosyltransferase 1A1enzyme

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT04742153	A Study of MRG002 in the Treatment of Patients With HER2-low Locally Advanced or Metastatic Breast Cancer (BC)	Trastuzumab vedotin	treatment	2	unknown_status
NCT01676753	Phase 1b Trial of Dinaciclib With Pembrolizumab for Advanced Breast Cancer	Dinaciclib Pembrolizumab	treatment	1	completed
NCT00748553	A Phase I/II Clinical Trial of Vidaza With Abraxane in Patients With Advanced/Metastatic Solid Tumors and Breast Cancer	No drug interventions	treatment	1 / 2	completed
NCT05187832	A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer	No drug interventions	treatment	1	recruiting
NCT03767335	MEN1611 With Trastuzumab (+/- Fulvestrant) in Metastatic Breast Cancer	CH-5132799 Fulvestrant Trastuzumab	treatment	1	completed
NCT02154776	Dose Escalation Study of LEE011 in Combination With Buparlisib and Letrozole in HR+, HER2-negative Post-menopausal Women With Advanced Breast Cancer.	Buparlisib Letrozole Ribociclib	other	1	completed
NCT05932667	Milademetan and Fulvestrant in GATA3-mutant, ER+HER- Advanced or Metastatic Breast Cancer	No drug interventions	treatment	2	terminated
NCT06105632	A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment	No drug interventions	treatment	3	recruiting
NCT05519059	Pelareorep and Paclitaxel Injection in Chinese Patients With Advanced or Metastatic Breast Cancer	No drug interventions	treatment	1	completed
NCT06201234	Evaluating the Addition of Elacestrant (Oral SERD) to Niraparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer	No drug interventions	treatment	2	not_yet_recruiting
NCT01226316	Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules	No drug interventions	treatment	1	active_not_recruiting
NCT01625286	Investigating Safety, Tolerability and Efficacy of AZD5363 When Combined With Paclitaxel in Breast Cancer Patients	No drug interventions	treatment	1 / 2	completed
NCT04494425	Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer	No drug interventions	treatment	3	active_not_recruiting